Cystic Fibrosis - Drug Pipeline Analysis and Market Forecasts to 2015
Advertisement
http://www.reportlinker.com/p0167274/Cystic-Fibrosis---Drug-Pipeline-Analysis-and-Market-Forecasts-to-2015.html
Cystic Fibrosis - Drug Pipeline Analysis and Market Forecasts to 2015
Advertisement
Summary
GlobalData, the industry analysis specialist's new report, "Cystic Fibrosis - Drug Pipeline Analysis and Market Forecasts to 2015" is an essential source of information and analysis on the global cystic fibrosis (CF) market. The report identifies the key trends shaping and driving the global CF market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global CF sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts.
Scope
The scope of the report includes:
Reasons to buy
The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
Table of Contents
1 Cystic Fibrosis Market: Executive Summary
1.1 The Cystic Fibrosis Market is Forecast to Show Positive Growth until 2015
1.2 Major Companies Focus on Cystic Fibrosis Drug Development Landscape
1.3 Current Treatment Options are Unsuccessful in Meeting Market demand
1.4 Strong Pipeline Candidates Raise Hope for Cystic Fibrosis Treatment Paradigm
1.5 Unmet Need Remains Unaddressed
2 Table Of Contents
2.1 List of Tables
2.2 List of Figures
3 Global Cystic Fibrosis Market: Market Characterization
3.1 Overview
3.2 Cystic Fibrosis Market Size
3.3 Cystic Fibrosis Market Forecast and CAGR
3.4 Drivers and Barriers for Cystic Fibrosis Market
3.4.1 Drivers for Cystic Fibrosis Market
3.4.2 Barriers for Cystic Fibrosis Market
3.5 Opportunity and Unmet Need
3.6 Key Takeaway
4 Global Cystic Fibrosis Market: Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profile for the Major Marketed Products in Cystic Fibrosis Market
4.3.1 Tobi (Tobramycin Inhalation Solution, USP)
4.3.1.1 Overview
4.3.1.2 Efficacy
4.3.1.3 Safety Profile
4.3.1.4 Pricing
4.3.1.5 Clinical Study Details
4.3.2 Pulmozyme� (Dornase Alfa)
4.3.2.1 Overview
4.3.2.2 Efficacy
4.3.2.3 Safety
4.3.2.4 Pricing
4.3.2.5 Clinical Study Details
4.3.3 ZENPEP(TM) (Pancrelipase capsules)
4.3.3.1 Overview
4.3.3.2 Efficacy
4.3.3.3 Safety
4.3.3.4 Clinical Study Details
4.4 Key Takeaway
5 Global Cystic Fibrosis Market: Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.2.1 Technology Trends Analytic Framework
5.3 Cystic Fibrosis Therapeutics -Promising Drugs under Clinical Development
5.4 Molecule Profile for Promising Drugs under Clinical Development
5.4.1 Cayston (Aztreonam lysine)
5.4.1.1 Overview
5.4.1.2 Efficacy
5.4.1.3 Safety
5.4.1.4 Clinical Study Details
5.4.2 Denufosol Tetrasodium Inhalation Solution (INS37217)
5.4.2.1 Overview
5.4.2.2 Efficacy
5.4.2.3 Safety
5.4.2.4 Clinical Study Details
5.4.3 VX-770
5.4.3.1 Overview
5.4.3.2 Efficacy
5.4.3.3 Safety
5.4.3.4 Clinical Study Details
5.4.4 Bronchitol
5.4.4.1 Overview
5.4.4.2 Efficacy
5.4.4.3 Safety
5.4.4.4 Clinical Study Details
5.4.5 Ataluren (PTC-124)
5.4.5.1 Overview
5.4.5.2 Efficacy
5.4.5.3 Safety
5.4.5.4 Clinical Study Details
5.5 Cystic Fibrosis Therapeutics Market - Clinical Pipeline by Mechanism of Action
5.6 Cystic Fibrosis Pipeline - Pipeline by Clinical Phases of Development
5.6.1 Cystic Fibrosis Therapeutics - Regulatory and Phase III Clinical Pipeline
5.6.2 Cystic Fibrosis Therapeutics - Phase II Clinical Pipeline
5.6.3 Cystic Fibrosis Therapeutics - Phase I Clinical Pipeline
5.6.4 Cystic Fibrosis Therapeutics - Preclinical Pipeline
5.7 Discontinued / Suspended Drugs for Cystic Fibrosis
5.8 Key Takeaway
6 Global Cystic Fibrosis Market: Implications for Future Market Competition
7 Global Cystic Fibrosis Market: Future Players in Cystic Fibrosis Market
7.1 Introduction
7.2 Cystic Fibrosis Foundation Therapeutics, Inc.
7.2.1 Overview
7.2.2 Cystic Fibrosis Portfolio
7.2.2.1 Marketed Products
7.2.2.2 Pipeline Products
7.2.3 Cystic Fibrosis Product Portfolio
7.2.3.1 TIP (Tobramycin Inhalation Powder)
7.2.3.2 MP-376 (Levofloxacin Solution for Inhalation)
7.2.3.3 Arikace(TM) (Liposomal amikacin for inhalation)
7.2.3.4 Moli 1901(Lancovutide)
7.2.3.5 Gene Therapy (Copernicus Therapeutics)
7.2.3.6 KB001
7.2.3.7 Triolex(TM) (HE3286)
7.3 Pharmaxis Ltd
7.3.1 Overview
7.3.2 Respiratory Portfolio
7.3.2.1 Marketed Products
7.3.2.2 Pipeline Products
7.3.3 Cystic Fibrosis Product Portfolio
7.3.3.1 Bronchitol
7.4 Gilead Sciences, Inc
7.4.1 Overview
7.4.2 Respiratory Portfolio
7.4.2.1 Marketed Products
7.4.2.2 Pipeline Products
7.4.3 Cystic Fibrosis Product Portfolio
7.4.3.1 Aztreonam for Inhalation Solution
7.4.3.2 GS9310/11(inhaled fosfomycin/Tobramycin)
7.4.3.3 GS9411
7.5 Vertex Pharmaceuticals, Inc
7.5.1 Overview
7.5.2 Respiratory Portfolio
7.5.2.1 Marketed Products
7.5.2.2 Pipeline Products
7.5.3 Cystic Fibrosis Product Portfolio
7.5.3.1 VX-770
7.5.3.2 VX-809
7.6 AstraZeneca
7.6.1 Overview
7.6.2 Respiratory Portfolio
7.6.2.1 Marketed Products
7.6.2.2 Pipeline Products
7.6.3 Cystic Fibrosis Product Portfolio
7.6.3.1 AZD9668
7.7 PARI Pharma
7.7.1 Overview
7.7.2 Respiratory Portfolio
7.7.2.1 Marketed Products
7.7.2.2 Pipeline Products
7.7.3 Cystic Fibrosis Product Portfolio
7.7.3.1 PARI Tobramycin 100 (inhalation)
8 Global Cystic Fibrosis Market: Appendix
8.1 Definitions
8.2 Acronyms
8.3 Research Methodology
8.3.1 Coverage
8.3.2 Secondary Research
8.3.3 Forecasting
8.3.3.1 Epidemiology-based Forecasting
8.3.4 Primary Research
8.3.5 Expert Panel validation
8.4 Contact Us
8.5 Disclaimer
8.6 Sources
List of Tables
Table 1: Global Cystic Fibrosis Therapeutics Market, Revenue ($m), 2000-2015
Table 2: Major Marketed Products Comparison in Cystic Fibrosis Market, 2009
Table 3: Cystic Fibrosis Therapeutics - Most Promising Drugs Under Clinical Development, 2009
Table 4: Cystic Fibrosis Therapeutics - Phase III Clinical Pipeline, 2009
Table 5: Cystic Fibrosis Therapeutics - Phase II Clinical Pipeline, 2009
Table 6: Cystic Fibrosis Therapeutics - Phase I Clinical Pipeline, 2009
Table 7: Cystic Fibrosis Therapeutics - Preclinical Pipeline, 2009
Table 8: List of Discontinued Drugs for Cystic Fibrosis, 2009
Table 9: CFFT - Cystic Fibrosis Marketed Products, 2009
Table 10: CFFT - Cystic Fibrosis Pipeline Products, 2009
Table 11: Pharmaxis Ltd - Respiratory Marketed Product, 2009
Table 12: Pharmaxis Ltd - Respiratory Pipeline Products, 2009
Table 13: Gilead Sciences, Inc - Respiratory Pipeline Products, 2009
Table 14: Vertex Pharmaceuticals Inc- Respiratory Pipeline Products, 2009
Table 15: AstraZeneca - Respiratory Marketed Products, 2009
Table 16: AstraZeneca - Respiratory Pipeline Products, 2009
Table 17: Pari Pharma - Respiratory Marketed Products, 2009
Table 18: Pari Pharma - Respiratory Pipeline Products, 2009
List of Figures
Figure 1: Global Cystic Fibrosis Market, Revenue ($m), 2000-2015
Figure 2: Opportunity and Unmet Need, 2009
Figure 3: Strategic Competitor Assessment of the Major Marketed Products in Cystic Fibrosis, 2009
Figure 4: Technology Trends Analytic Framework of the Cystic Fibrosis Pipeline, 2009
Figure 5: Technology Trends Analytic Framework of the Cystic Fibrosis Pipeline - Description, 2009
Figure 6: Cystic Fibrosis Therapeutics Market - Clinical Pipeline by Mechanism of Action, 2009
Figure 7: Cystic Fibrosis Pipeline by Phase of Clinical Development, 2009
Figure 8: Implications for Future Market Competition in the Cystic Fibrosis Market, 2009
Figure 9: Cystic Fibrosis Therapeutics Market - Clinical Pipeline by Company, 2009
Figure 10: GlobalData Methodology
Figure 11: GlobalData Market Forecasting Model
Companies mentioned
Novartis Pharmaceuticals, Genentech, Eurand Pharmaceuticals, Gilead Sciences, Inspire Pharmaceuticals, Vertex Pharmaceuticals, Cystic Fibrosis Foundation Therapeutics, Inc, Pharmaxis Ltd, PTC Therapeutics , Genzyme, AstraZeneca, PARI Pharma
To order this report: Pharmaceutical Industry: Cystic Fibrosis - Drug Pipeline Analysis and Market Forecasts to 2015
More Market Research Report
-- Annualized global cystic fibrosis market revenues data from 2000 to 2008, forecast forward for 7 years to 2015. -- Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan. -- Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action include antibiotics and anti-infective agents, Ion transport modulators, anti-inflammatory agents, Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulators, Nutritional supplements and Pancreatic Enzyme Replacement Therapy (PERT) classes of drugs. -- Analysis of the current and future market competition in the global CF market. Key market players covered are Cystic Fibrosis Foundation Therapeutics, Inc (CFFT), Pharmaxis, Gilead Sciences, Vertex Pharma, AstraZeneca and Pari Pharma. -- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. -- Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with cystic fibrosis.
SOURCE Reportlinker
